awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38950577-1339C860-23EF-43E6-9A12-CEE424E1C6BF
Q38950577-1339C860-23EF-43E6-9A12-CEE424E1C6BF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38950577-1339C860-23EF-43E6-9A12-CEE424E1C6BF
Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
P2860
Q38950577-1339C860-23EF-43E6-9A12-CEE424E1C6BF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38950577-1339C860-23EF-43E6-9A12-CEE424E1C6BF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1e1505a0dc3a9016d166f6b5226b6b0f2cc2b5d1
P2860
coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)